---
title: "Pharming To Present New Leniolisib Pediatric And CVID Data At CIS 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285556475.md"
description: "Pharming Group N.V. (PHAR) will present new data on Leniolisib for pediatric patients with activated PI3Kd syndrome and clinical experience in Common Variable Immunodeficiency (CVID) at the CIS 2026 Annual Meeting in New Orleans, scheduled for May 6-9, 2026. Presentations will include interim safety and efficacy outcomes from a long-term study in children aged 4-11, real-world data in CVID, and findings from the APDS-CHOIR registry. The stock closed at $16.40, up 1.42%, but is down 19.63% in pre-market trading at $13.18."
datetime: "2026-05-07T12:55:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285556475.md)
  - [en](https://longbridge.com/en/news/285556475.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285556475.md)
---

# Pharming To Present New Leniolisib Pediatric And CVID Data At CIS 2026

(RTTNews) - Pharming Group N.V. (PHAR) will deliver multiple scientific presentations at the Clinical Immunology Society (CIS) 2026 Annual Meeting, taking place May 6-9, 2026, in New Orleans.

The presentations, are scheduled across May 7 and May 8, will highlight new data on Leniolisib in pediatric patients with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS) as well as clinical experience in Common Variable Immunodeficiency (CVID) and related immune dysregulation disorders.

According to the company, the pediatric Leniolisib presentation will focus on interim safety and efficacy outcomes from an open-label long-term extension study in children aged 4-11, supporting Pharming's efforts to expand access beyond the currently approved age group.

Additional presentations will describe real-world and clinical-experience data in CVID and immune-dysregulation conditions, findings from the APDS-CHOIR registry, caregiver- and clinician-reported symptom assessments in pediatric APDS, and a systematic literature review on the use of Sirolimus and immunoglobulin replacement therapy in APDS.

Pharming and its academic collaborators will also present the design and baseline characteristics of an ongoing Phase 2 study evaluating Leniolisib in primary immunodeficiencies with enhanced PI3K pathway signaling.

PHAR has traded between $8.69 and $16.74 over the past year. The stock closed Wednesday's trading at $16.40, up 1.42%. In pre-market trading the stock is at $13.18, down 19.63%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [PHAR.US](https://longbridge.com/en/quote/PHAR.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)
- [Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program](https://longbridge.com/en/news/287222906.md)
- [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)
- [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)